• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lexaria Bioscience Corp (NQ: LEXX )

    3.020 +0.140 (+4.86%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 222,283
    Open 2.800
    Bid (Size) 2.920 (3)
    Ask (Size) 3.020 (1)
    Prev. Close 2.880
    Today's Range 2.800 - 3.050
    52wk Range 0.7598 - 6.850
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing
    Via CannabisNewsWire
    Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing
    Via Investor Brand Network

    Performance

    YTD
    +134.11%
    +134.11%
    1 Month
    +13.96%
    +13.96%
    3 Month
    +34.82%
    +34.82%
    6 Month
    +98.68%
    +98.68%
    1 Year
    +255.29%
    +255.29%

    More News

    Read More
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
    Via ACCESSWIRE
    Lexaria Preparing For Strategic Growth
    Via ACCESSWIRE
    Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
    Via ACCESSWIRE
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Issuance of Three New Patents, Growing Portfolio to 46 Granted Patents Worldwide
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Makes Management Announcement, Plans for Strategic Growth
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
    Via ACCESSWIRE
    Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
    Via ACCESSWIRE
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Replicate Results from First GLP-1 Study Following CRO Contract Award for 12-Week Chronic Human Study
    Via Investor Brand Network
    LEXX Stock Earnings: Lexaria Bioscience Misses EPS, Misses Revenue for Q3 2024
    Via InvestorPlace
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property Product Safety
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property Product Safety
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures New Patents for Antiviral Drug Delivery, Treating Epilepsy
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Favorable Strategic Partnering with Leading GLP-1 Players
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Second Round of Dosing for Human Pilot Study #2; Set to Complete Third Study Arm in Early July
    Via Investor Brand Network
    7 A-Rated Penny Stocks to Beat June Gloom
    Via InvestorPlace
    HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Engages CRO for DehydraTECH GLP-1 Human Study
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires CRO; Set for First Tirzepatide Molecule Study
    Via Investor Brand Network
    7 A-Rated Biotech Stocks Worth Betting on in June
    Via InvestorPlace
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Patent Portfolio to 43 Granted Patents Worldwide
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property Product Safety
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property Product Safety
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.